DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Samsung Biologics has announced plans to acquire Swiss contract drug manufacturer PolyPeptide in an all-cash deal valued at approximately 1.46 billion Swiss francs ($1.81 billion), strengthening its position in the fast-growing peptide therapeutics market.
Under the proposed transaction, Samsung Biologics will offer 44.31 Swiss francs per share, representing a 6.1% premium to PolyPeptide’s closing price of 41.75 Swiss francs on Friday. The South Korean biotech company expects to launch the tender offer by the end of August, with the acquisition targeted for completion before the end of the year.
The acquisition is part of Samsung Biologics’ strategy to expand its contract development and manufacturing capabilities, particularly in peptide-based medicines. The company sees strong growth opportunities in therapies for obesity and diabetes, including GLP-1 drugs, a segment experiencing surging global demand.
PolyPeptide’s board of directors has unanimously recommended that shareholders accept the offer, signaling strong support for the transaction.
Samsung Biologics also said it intends to acquire all remaining shares after the tender offer through a squeeze-out process, allowing it to delist PolyPeptide from the SIX Swiss Exchange and operate the company as a wholly owned subsidiary.
The deal already has the backing of Draupnir Holding, PolyPeptide’s largest shareholder, which controls approximately 55.65% of the company. Draupnir confirmed it will tender all of its shares into Samsung Biologics’ offer.
Earlier this year, PolyPeptide disclosed that Draupnir was reviewing strategic options for its majority stake. Draupnir’s parent organization, the Cryosphere Foundation, has previously been linked to Swedish billionaire Frederik Paulsen.
If completed, the acquisition would significantly enhance Samsung Biologics’ manufacturing portfolio and strengthen its presence in the rapidly expanding global market for peptide-based pharmaceutical ingredients. The move also reflects growing competition among contract drug manufacturers seeking to capitalize on increasing demand for innovative biologic and metabolic disease treatments.
